Compare NBHC & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBHC | NNNN |
|---|---|---|
| Founded | 2009 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2011 | N/A |
| Metric | NBHC | NNNN |
|---|---|---|
| Price | $39.65 | $21.18 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $45.33 | N/A |
| AVG Volume (30 Days) | ★ 464.5K | 42.1K |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.19% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.85 | N/A |
| Revenue | ★ $47,100,000.00 | N/A |
| Revenue This Year | $39.32 | N/A |
| Revenue Next Year | $6.74 | N/A |
| P/E Ratio | ★ $14.11 | $446.57 |
| Revenue Growth | ★ 2.86 | N/A |
| 52 Week Low | $32.83 | $5.91 |
| 52 Week High | $42.99 | $55.65 |
| Indicator | NBHC | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 42.30 | 41.30 |
| Support Level | $37.79 | $19.25 |
| Resistance Level | $40.97 | $30.70 |
| Average True Range (ATR) | 1.13 | 2.16 |
| MACD | -0.19 | -0.20 |
| Stochastic Oscillator | 19.01 | 6.00 |
National Bank Holdings Corp is a bank holding company. It provides various banking products and financial services to commercial, business, and consumer clients in the United States. The company offers deposit products including checking accounts, savings accounts, money market accounts, and other deposit accounts, including fixed-rate and fixed-maturity time deposits. It also provides commercial and industrial loans and leases. In addition, it offers treasury management solutions comprising online and mobile banking, commercial credit cards, wire transfers, automated clearing house, and electronic bill payments.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.